Novel Agents in Inflammatory Bowel Disease
For nearly two decades, novel therapies for IBD have primarily targeted the same cell signaling cytokine, tumor necrosis factor alpha (TNF-α). TNF is a key cytokine in inflammatory pathways, and dysregulation of TNF production has been implicated in both ulcerative colitis (UC) and Crohn’s disease (CD). This strategy has been and continues to be effective but not wholly effective. Nearly a third of patients do not respond to this strategy and others flare despite initial control. This chapter focuses primarily on novel agents other than anti-TNFs that have either been recently released or under late-stage investigation and likely to progress to market.
KeywordsCrohn’s Ulcerative colitis Biologic therapy Anti-integrin Janus kinase inhibitor Sphingosine-1-phosphate receptor inhibitor IL12/IL23 inhibitor Anti-SMAD7
- 14.Reinisch W, Sandborn W, Danese S, et al. A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: results of the TURANDOT study. Gastroenterology. 2015;148:S1193–5.CrossRefGoogle Scholar
- 17.Reinisch W, Vermeire S, Cataldi F, et al. Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of crohn’s disease patients who are anti-TNF inadequate responders: results from the Tosca study. Gastroenterology. 2014;146:S150-S.CrossRefGoogle Scholar
- 26.Feagan BG, Sandborn W, Panes J, et al. Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn’s disease: results of a randomized, double-blind, placebo-controlled phase II study. Gastroenterology. 2016;150:S1266-S.CrossRefGoogle Scholar
- 29.Feagan B. Update on tofacitinib for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12:572–4.Google Scholar
- 31.Sandborn W, Sands B, Danese S, et al. Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial. J Crohns Colitis. 2017;10:S15-S.Google Scholar